Summary
Background Antibiotic resistance (ABR) is a major concern for global health. However, factors driving its emergence and dissemination are not fully understood. Identification of such factors is crucial to explain heterogeneity in ABR rates observed across space, time and species and antibiotics.
Methods We analyzed count data of resistant isolates from 51 countries over 2006-2019 for nine drug-bug pairs from the surveillance database ATLAS. We characterized ABR spatial and temporal patterns and used a mixed-effect negative binomial model, accounting for country-year dependences with random effects (RE), to investigate associations with potential drivers including antibiotic sales, economic and health indicators, meteorological data, population density and tourism.
Findings ABR patterns were strongly country and drug-bug pair dependent. In 2019, median ABR rates ranged from 6·3% for carbapenem-resistant (CR) Klebsiella pneumoniae to 72·3% for CR-Acinetobacter baumannii, with heterogeneity across countries (up to 50·2% of interquartile range for CR-A. baumannii). Over 2006-2019, carbapenem resistance was on the rise in >75% of investigated countries but no global trend was observed for other resistances. Multivariable analyses identified significant associations of ABR with antibiotic sales, but only in fluoroquinolone-resistant Escherichia coli, CR-A. baumannii and penicillin-resistant Streptococcus pneumoniae; with temperature in investigated Enterobacterales but not in other drug-bug pairs; and with the health system quality for most drug-bug pairs, except in Enterococci and S. pneumoniae. Despite wide consideration of possible explanatory variables, drug-bug pairs still showed high spatial RE variance.
Interpretation These results reflect the diversity found among human bacterial pathogens and stress the difficulty to generalize global antibiotic resistance findings.
Funding Independent research Pfizer Global Medical Grant; ANR Labex IBEID (ANR-10-LABX-62)
Competing Interest Statement
ER work was funded by an independent research Pfizer Global Medical Grant (number 57504809). PG and LW received consulting fees from Pfizer for an unrelated project. LW received consulting fees from HEVA and IQVIA for unrelated projects.
Funding Statement
Funding: Independent research Pfizer Global Medical Grant; ANR Labex IBEID (ANR-10-LABX-62)
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos